Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate
Author: Buchanan, G.
Birrell, S.
Peters, A.
Bianco-Miotto, T.
Ramsay, K.
Cops, E.
Yang, M.
Harris, J.
Simila, H.
Moore, N.
Bentel, J.
Ricciardelli, C.
Horsfall, D.
Butler, L.
Tilley, W.
Citation: Cancer Research, 2005; 65(18):8487-8496
Publisher: Amer Assoc Cancer Research
Issue Date: 2005
ISSN: 0008-5472
Statement of
Grant Buchanan, Stephen N. Birrell, Amelia A. Peters, Tina Bianco-Miotto, Katrina Ramsay, Elisa J. Cops, Miao Yang, Jonathan M. Harris, Henry A. Simila, Nicole L. Moore, Jacqueline M. Bentel, Carmella Ricciardelli, David J. Horsfall, Lisa M. Butler and Wayne D. Tilley
Abstract: Previously, we reported that androgen receptor (AR), but not estrogen receptor (ER) or progesterone receptor (PR), is predictive of response to the synthetic progestin, medroxyprogesterone acetate (MPA), in a cohort of 83 patients with metastatic breast cancer. To further investigate the role of AR in determining response to MPA in this cohort, we analyzed AR levels by immunohistochemistry with two discrete antisera directed at either the NH2 or the COOH termini of the receptor. Compared with tumors that responded to MPA (n = 31), there was a significant decrease in the intensity and extent of AR immunoreactivity with both AR antisera in tumors from nonresponders (n = 52). Whereas only a single AR immunostaining pattern was detected in responders to MPA, reflecting concordance of immunoreactivity with the two AR antisera, tumors from nonresponders exhibited four distinct AR immunostaining patterns: (a) concordance with the two antibodies (31%), (b) staining only with the COOH-terminal antibody (33%), (c) staining only with the NH2-terminal antibody (22%), or (d) no immunoreactivity with either NH2- or COOH-terminal antibody (14%). DNA sequencing and functional analysis identified inactivating missense gene mutations in the ligand-binding domain of the AR in tumors from two of nine nonresponders positive with the NH2-terminal AR antisera but negative for COOH-terminal immunoreactivity and lacking specific, high-affinity dihydrotestosterone binding in tumor cytosol fractions. Tumors with more AR than the median level (37 fmol/mg protein) had significantly lower levels of PR (30 fmol/mg protein) than tumors with low AR (PR; 127 fmol/mg protein) despite comparable levels of ER. Ligand-dependent activation of the AR in human T47D and MCF-7 breast cancer cells resulted in inhibition of estradiol-stimulated cell proliferation and a reduction in the capacity of the ER to induce expression of the PR. These effects could be reversed using a specific AR antisense oligonucleotide. Increasing the ratio of AR to ER resulted in a greater androgen-dependent inhibition of ER function. Collectively, these data suggest that reduced levels of AR or impaired AR function contribute to the failure of MPA therapy potentially due to abrogation of the inhibitory effect of AR on ER signaling.
Keywords: COS Cells
Cell Line, Tumor
Breast Neoplasms
Protein Isoforms
Receptors, Androgen
Receptors, Estrogen
Antineoplastic Agents, Hormonal
Radioligand Assay
Signal Transduction
Protein Conformation
Drug Resistance, Neoplasm
Medroxyprogesterone Acetate
Chlorocebus aethiops
Rights: © 2005 American Association for Cancer Research
DOI: 10.1158/0008-5472.CAN-04-3077
Appears in Collections:Aurora harvest 6
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.